key: cord-0979389-8k8gt7qh
authors: Ren, Ke
title: Grand Challenges in Musculoskeletal Pain Research: Chronicity, Comorbidity, Immune Regulation, Sex Differences, Diagnosis, and Treatment Opportunities
date: 2020-10-23
journal: Front Pain Res (Lausanne)
DOI: 10.3389/fpain.2020.575479
sha: a87b19d34d412f1dc93c900bf7e86402a2f185a0
doc_id: 979389
cord_uid: 8k8gt7qh

nan

Musculoskeletal pain involves bones, joints, and related muscular tissues and includes most debilitating pain conditions such as low back pain, arthritic pain, and widespread muscle pain. Chronic musculoskeletal pain is the most predominant among chronic pain conditions and presents a serious challenge to primary care. Pain arising from musculoskeletal tissues is characteristic of deep pain and has important differences from that of cutaneous pain [ Table  1 ; (1) ]. Compared to cutaneous tissue injury, the injection of the same amount of inflammatory agent into the joint induces more intense inflammation and greater and more widespread neuronal activation in the pain transmission pathways (2) . Musculoskeletal nociceptive inputs appear more effective in inducing neuronal excitation and produce greater sensory disturbances (3, 4) , which may explain predominant chronic pain conditions involving deep tissues. The underlying etiology and pathology of chronic musculoskeletal pain conditions are poorly understood even after decades of research.

Human muscle pain can be induced experimentally by injecting the hyperalgesic agents such as hypertonic saline (5) , capsaicin (6) , glutamate (7) , serotonin (8) , or nerve growth factor (9, 10) into the muscle. To avoid invasive procedures, a short-wave diathermy-induced

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. human muscle pain model has been developed (11) . These human muscle pain models help to advance our understanding of the mechanisms and improve the treatment of muscle pain. A limitation of these models, however, is that the induced muscle pain hypersensitivity would resolve within minutes to hours [e.g., (5, 12) ]. Nerve growth factor induces relatively long-lasting hyperalgesia for 4-7 days to a few weeks after injection into the muscle in humans (9, 13, 14) . Chronic pain is defined as pains that persist or recur for longer than 3 months (15) . While acute and chronic pain shares similar neural mechanisms, chronic pain is underlying by distinct mechanisms of central sensitization and still unsettled involvement of the immune system (16) (17) (18) . Although these human experimental models mimic aspects of acute or persistent pain, they are not necessarily suitable for studying pain chronicity, a deteriorating and devastating problem for patients.

Animal persistent musculoskeletal pain models have been developed to simulate chronic pain conditions in humans. A variety of methods can be used to assess muscle/joint pain in animals, including evoked nocifensive reflex and vocalization, movement-related measures such as weight-bearing and gait analysis, functional measures such as bite force and grip force, spontaneous nociception such as home cage monitoring, scratching behaviors, and grimace scale. To mimic human rheumatic disease, polyarthritis was induced by injecting complete Freund's adjuvant (CFA) into the base of the rat's tail (19) . Pain hypersensitivity occurs in multiple joints after 10 days and lasts up to 3 weeks. Later studies revealed that a systemic disease was induced in this model that included skin lesions, destruction of bone and cartilage, impairment of liver function, and lymphadenopathy, which made it difficult to differentiate pain behavior from generalized malaise and debilitation, and led to ethical concerns (20) . Injection of inflammatory irritants into the joints and muscles, including CFA, carrageenan, zymosan, mustard oil, formalin, capsaicin, bee venom, acidic saline, lipopolysaccharide, inflammatory cytokines, monosodium iodoacetate, and sodium urate crystals, has been used to produce tissue injury and hyperalgesia [(21), review]. These models mainly reflect early injury responses and there is still a significant challenge to develop models that can be translated into human chronic musculoskeletal pain conditions [see (22) ].

Surgical interventions are employed to model chronic low back pain, the most commonly seen chronic musculoskeletal pain [reviewed in (23) ]. The procedures include the compression of the dorsal root ganglion (24) , disruption of the lumbar intervertebral disc (25) , implantation of tissues into the lumbar epidural space to mimic disc herniation (26), injection of complete Freund's adjuvant into the intervertebral disc or nucleus pulposus (27) , and surgical application of zymosan into the epidural space to induce inflammation of the dorsal root ganglion (28) . These approaches lead to behavioral hyperalgesia resembling human low back pains such as discogenic and radicular back pain and low back pain related to local inflammation. The pain hypersensitivity after surgical interventions can last for up to months (24, 25, 27) , longer than that after a simple injection of algesic mediators. To mimic soft tissue musculoskeletal pain such as tendinopathy, a constriction injury of the tendon of the rat masseter muscle produces pain hypersensitivity that lasts for months (29, 30) . These models may be employed to identify distinct mechanisms that contribute to the development of chronic musculoskeletal pain.

The new International Classification of Diseases-11 has updated the chronic pain classification to include the Primary chronic pain category to designate chronic pain that cannot directly be ascribed to any disease of structural injury. Fibromyalgia, a chronic condition characterized by widespread pain involving musculoskeletal tissues, is a type of primary chronic musculoskeletal pain and women appear to be affected more than men (31, 32) . A reserpine myalgia model has been presented to model fibromyalgia in animals (33) . In this model, a daily subcutaneous injection of reserpine (1 mg/kg) was repeated for 3 consecutive days induced decreased muscle pressure threshold and allodynia. While the reserpine approach is promising, the model's relevance to fibromyalgia is still an issue. The reserpine-induced myalgia would only persist for about 1 week and the sex difference in fibromyalgia prevalence is not reproduced (33, 34) . Reserpine depletes monoamine neurotransmitters norepinephrine, dopamine, and serotonin by inhibiting vesicular monoamine transporters (35) . Reserpine-induced pain suggests that these monoamines exert a net inhibitory effect on nociception. It is interesting to note that Catechol-Omethyltransferase (COMT) metabolizes catecholamines, but inhibition of COMT leads to enhanced catecholamine levels and pain hypersensitivity via beta2/3-adrenoceptors (36) . The imbalance of monoamines in fibromyalgia and functional pain syndrome requires further investigation.

The preclinical muscle/bone/joint pain models have contributed greatly to our understanding of the biological mechanisms underlying musculoskeletal pain. However, there are still gaps in our understanding, particularly with the development of pain chronicity. Most studies have settled to use the observed persistent pain within days or a couple of weeks after the injury as a surrogate of chronic pain in humans, despite that the early persistent pain could still be a type of acute pain and may miss characteristics of chronic pain that occurs late. Recent studies have reported month-long upregulation of microglial markers in the spinal cord after nerve injury and differential cytokine profiles between the early and late phases of hyperalgesia (37) . The transcription factor NF-kB is known for its immediate proinflammatory role, but it also contributes to the resolution of inflammation at the late phase of inflammation (38) . Reevaluation of the CFA inflammatory hyperalgesia model indicates that the temporal course of mechanical hyperalgesia consists of an initial developing phase with peak hyperalgesia at 4-24 h, a subsequent attenuating phase of a few weeks, followed by a late persistent (chronic) phase that lasted for months (18) . Importantly, different cellular mechanisms are involved in the early acute phase and late chronic phase of CFA-induced hyperalgesia, as suggested by a late downregulation of astroglial glutamate transporters that occurs at a time when hyperalgesia transitions into the persistent chronic phase (18) . Thus, preclinical studies on chronic musculoskeletal pain need to attend to the late chronic phase of pain hypersensitivity. The central mechanisms involved in the transition of chronic muscle pain should also be studied (39, 40) . We are challenged to differentiate the factors relevant to the transition and maintenance of musculoskeletal pain chronicity. Myalgia is one of the major symptoms of Covid-19 (41, 42) . It remains to be seen whether it could develop into a chronic problem.

Widespread pain is commonly seen in musculoskeletal pain conditions, which is characteristic of deep tissue pain that refers to the areas remote from injury. The temporomandibular joint disorders (TMJD) patients not only have pain in the TMJ and muscles of mastication but also pain in other muscles and joints (43, 44) . Somewhat conceptually overlapping with widespread pain, patients with chronic musculoskeletal pain frequently have other comorbid pain conditions: fibromyalgia and TMJD (45, 46) , migraine (47) , and visceral pain (48) , TMJD and headache (49) , and Ehlers-Danlos syndromes (joint pain) and Chiari Malformation (headache and neck pain) (50) . A causal relationship between the comorbid pain conditions is often difficult to determine regarding which condition triggers the other, but the involvement of multiple body structures suggests a centralmediated effect (51, 52) .

Widespread and comorbid muscle pains can be reproduced in animal models. Repeated unilateral injections of acidic saline into the gastrocnemius muscle of rats produce bilateral hyperalgesia that lasts for up to 30 days (53), which mimics persistent widespread muscle pain in humans. Unilateral injection of CFA into the masseter muscle induces bilateral behavioral hyperalgesia (54) . Combined masseter muscle inflammation and stress induce visceral hypersensitivity similar to that seen in comorbid TMJD and irritable bowel syndrome patients (55) . Interestingly, the inflammatory pain of the craniofacial muscle in rats can spread to the hind paw, but not vice versa (56) . Since primary sensory afferents from the craniofacial region project to a wide region of the brain, in contrast to distinct somatotopy of spinal afferents (57) , craniofacial musculoskeletal pain tends to induce comorbid pain conditions. The cellular mechanisms underlying the comorbidity of chronic musculoskeletal pain remain to be elucidated.

The development of persistent or chronic pain largely depends on the interactions between the nervous and immune systems, which involves glia that function as immune cells in the brain (17, 58) . The pain-related neuroimmune interactions are reciprocal and involve neurotransmitters and their receptors and immune mediators including cytokines and their receptors. In inflammatory hyperalgesia after injection of CFA into the masseter muscle, there is reactive astrogliosis, induction of proinflammatory cytokine IL-1b, and the coupling of NMDA receptor phosphorylation through IL-1 receptor signaling (59) . In ischemic myalgia, IL-1b signals through IL-1 receptor to upregulate acid-sensing ion channels to induce nociceptor sensitization (60) . Activation of P2X4 receptors on muscle macrophages leads to IL-1b release and muscle hyperalgesia (61) . Despite evidence from preclinical studies, clinical trials for the treatment of chronic pain with glial modulators have been unsuccessful (62) , which would suggest our incomplete understanding of the mechanisms. From imaging studies on chronic low back pain patients, it is observed that glial activity is negatively correlated with the levels of pain and IL-1b, suggesting an inhibitory role of glia related to the translocator protein, the marker used for glial activation in the study (63) . This inhibitory role of glial activity has largely been overlooked. The immune system provides balanced regulation to maintain normal function. The effector and regulatory T cells (Teffs and Tregs), for example, are pro-and anti-inflammatory, respectively (64) . The depletion of Tregs delays pain resolution (65) and enhances neuropathic pain (66) . Tumornecrosis factor (TNF) is proinflammatory through the TNFR1 while anti-inflammatory via TNFR2 (67) . Deletion of TNFR2 hampers, but activation of TNFR2 promotes recovery from neuropathic pain (65) . The known proinflammatory NF-kB pathway is involved in the development of pain hypersensitivity but also involved in bone marrow stromal cell-produced pain relief in a tendinopathy model (68) , suggesting dual roles of NF-kB in hyperalgesia and pain relief according to circumstances. These results suggest that the perturbation of the balanced or homeostatic immune regulation, not only immune activation, leads to disease conditions including chronic pain. In search of treatment strategies targeting the immune system, it would be ideal to return to homeostasis by strengthening the anti-inflammatory/protective profile, instead of simply shutting off immune activation.

The phenomenon of female predominance in chronic pain has been a topic of interest in recent decades (69) (70) (71) , which has led to the National Institutes of Health (NIH) mandate to include sex as a biological variable in NIH-funded Research (72) . Similar to other chronic pain conditions, women appear to be affected more than men by chronic and co-morbid musculoskeletal pain (73, 74) . While the relative prevalence of chronic pains in females and males can be quantified, we still need to find answers for the factors that contribute to these differences. In addition to document different levels of pain, more focus should be on the underlying differences in biology between males and females. Preclinical studies have shown male-specific involvement of Toll-like receptor 4 in persistent pain [see (71) ]. A recent report shows that the upregulation of genes that escape X chromosome inactivation is correlated to the development of co-morbid chronic musculoskeletal pain after a car accident in women, but not in men (74) . Elucidating the underlying differential biology in sex differences in pain would be important in avoiding the biased development of pain medicine.

Most of our knowledge about mechanisms of persistent pain is based on studies of cutaneous pain in animals, experimental subjects, and patients. Although it is tempting to generalize these findings to the pain of deep tissues such as muscle and joint, there are important differences between cutaneous and deep pain (Table 1) . Deep pains are diffuse and difficult to localize and represent a challenge in diagnosis and identification of etiology. It is often difficult to identify the direct cause of chronic musculoskeletal pain conditions such as TMJD and low back pain (75, 76) . The diagnosis and etiology of primary chronic musculoskeletal pain, fibromyalgia in particular (77) , are still under debate. Clinical studies in this area are much needed to improve the prevention and treatment of chronic musculoskeletal pain.

Managing musculoskeletal pain, especially when it becomes chronic, is a daily challenge in primary care. Commonly used pharmacological agents are NSAIDs, opioids, and steroids. Treatment options also include physical therapy, psychotherapy, mesotherapy, whole-body cryotherapy, and alternative or complementary therapies acupuncture, prolotherapy, percutaneous electrical nerve stimulation, and neuromuscular electrical stimulation. The current treatment provides some relief of acute or short-lasting pain but is unsatisfactory for chronic musculoskeletal pain (78) (79) (80) (81) . A recent report showed that transcranial magnetic stimulation of the prefrontal cortex attenuated long-term experimental muscle pain in human subjects (14) .

Cell-based therapy has shown tremendous promise in the management of chronic musculoskeletal pain in recent years. Patients with disc diseases receiving intradiscal injection of bone marrow concentrate show improvement of discogenic pain through up to a 3-year follow-up (82, 83) . The clinical improvement is attributable to mesenchymal stromal cells (MSCs) in the bone marrow. Clinical studies have shown the pain-reducing effect of multipotent MSCs in arthritic joint pain (84) (85) (86) , rotator cuff disease (87) , and discogenic pain (88, 89) . Large scale randomized controlled trials are necessary to substantiate these exciting findings.

Preclinical studies have addressed cellular mechanisms of MSC-produced musculoskeletal pain relief. In a tendon injury model, a single intravenous injection of bone marrow-derived MSCs produces long-term attenuation of behavioral hyperalgesia (30, 90) . The painattenuation is induced through the interaction of BMSCs with immune cells and mediators, that lead to suppression of proinflammatory cytokines and upregulation of anti-inflammatory cytokines (91) , inhibition of NMDA receptor phosphorylation (92) , and activation of endogenous opioid receptors (93) . One pitfall of systemic MSCs is that they tend to be trapped mostly in the lungs after transplantation (94, 95) and there is a case of reversible pulmonary embolism after multiple infusion of adipose tissue-derived MSCs (96) . However, MSCs injected locally to the spinal cord or transplanted directly into degenerated disc appeared to survive longer (97, 98) . The therapeutic effect of MSCs can be further improved by modifying their phenotype before transplantation (99, 100) . Studies on the use of therapeutic MSCs are rapidly expanding and we are looking forward to the establishment of novel treatment strategies for chronic musculoskeletal pain.

This author's work was supported by NIH grants DE025137, DE029187, and DE029946.

Basic mechanisms of pain associated with deep tissues

Orofacial deep and cutaneous tissue inflammation and trigeminal neuronal activation: Implications for persistent temporomandibular pain

Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat

Differential effects of cutaneous and deep application of inflammatory irritant on mechanoreceptive field properties of trigeminal brain stem nociceptive neurons

The effect of experimental muscle pain on the background electrical brain activity

Capsaicin-induced muscle hyperalgesia in the exercised and non-exercised human masseter muscle

Glutamate-evoked jaw muscle pain as a model of persistent myofascial TMD pain?

Pain and allodynia/hyperalgesia induced by intramuscular injection of serotonin in patients with fibromyalgia and healthy individuals

Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia

Nerve growth factor-evoked masseter muscle sensitization and perturbation of jaw motor function in healthy women

A new experimental model of muscle pain in humans based on short-wave diathermy

Activation of TRPV1 and TRPA1 leads to muscle nociception and mechanical hyperalgesia

Movement evoked pain and mechanical hyperalgesia after intramuscular injection of nerve growth factor: a model of sustained elbow pain

Left dorsolateral prefrontal cortex repetitive transcranial magnetic stimulation reduces the development of long-term muscle pain

A classification of chronic pain for ICD-11

Neuronal plasticity: increasing the gain in pain

Interactions between the immune and nervous systems in pain

Altered glial glutamate transporter expression in descending circuitry and the emergence of pain chronicity

Adjuvant-induced arthritis in rats: a possible animal model of chronic pain

Ankle joint urate arthritis (AJUA) in rats: an alternative animal model of arthritis to that produced by Freund's adjuvant

Animal models of inflammatory pain

Acid-induced experimental muscle pain and hyperalgesia with single and repeated infusion in human forearm

Animal models for studying the etiology and treatment of low back pain

Mechanical and thermal hyperalgesia and ectopic neuronal discharge after chronic compression of dorsal root ganglia

The rat intervertebral disk degeneration pain model: relationships between biological and structural alterations and pain

Pathomechanism of pain-related behavior produced by allografts of intervertebral disc in the rat

Complete Freund's adjuvant-induced intervertebral discitis as an animal model for discogenic low back pain

Robust increase of cutaneous sensitivity, cytokine production and sympathetic sprouting in rats with localized inflammatory irritation of the spinal ganglia

Long lasting pain hypersensitivity following ligation of the tendon of the masseter muscle in rats: a model of myogenic orofacial pain

Bone marrow stromal cells produce long-term pain relief in rat models of persistent pain

Fibromyalgia: a clinical review

The IASP classification of chronic pain for ICD-11: chronic secondary musculoskeletal pain

Biogenic amine depletion causes chronic muscular pain and tactile allodynia accompanied by depression: a putative animal model of fibromyalgia

Sex differences and estradiol involvement in hyperalgesia and allodynia in an experimental model of fibromyalgia

The ins and outs of vesicular monoamine transporters

Catechol-O-methyltransferase inhibition increases pain sensitivity through activation of both beta2-and beta3-adrenergic receptors

Spinal microglia are required for long-term maintenance of neuropathic pain

Possible new role for NF-kappaB in the resolution of inflammation

Transition to persistent orofacial pain after nerve injury involves supraspinal serotonin mechanisms

Motor cortex reorganization and impaired function in the transition to sustained muscle pain

Novel coronavirus infection (COVID-19) in humans: a scoping review and meta-analysis

Symptom burden and clinical profile of COVID-19 deaths: a rapid systematic review and evidence summary

Association between temporomandibular disorders and pain in other regions of the body

Cervical muscle tenderness in temporomandibular disorders and its associations with diagnosis, disease-related outcomes, and comorbid pain conditions

The effect of fibromyalgia and widespread pain on the clinically significant temporomandibular muscle and joint pain disorders-a prospective 18-month cohort study

Comorbidity between fibromyalgia and temporomandibular disorders: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol

Impact of migraine on fibromyalgia symptoms

Visceral pain as a triggering factor for fibromyalgia symptoms in comorbid patients

Headache attributed to TMD is associated with the presence of comorbid bodily pain: a case-control study

Neurological and spinal manifestations of the Ehlers-Danlos syndromes

Bilateral widespread mechanical pain sensitivity in women with myofascial temporomandibular disorder: evidence of impairment in central nociceptive processing

What are the predictors of altered central pain modulation in chronic musculoskeletal pain populations? A systematic review

Unilateral intramuscular injections of acidic saline produce a bilateral, long-lasting hyperalgesia

Trigeminal-rostral ventromedial medulla circuitry is involved in orofacial hyperalgesia contralateral to tissue injury

A clinically relevant animal model of temporomandibular disorder and irritable bowel syndrome comorbidity

Inflammation of craniofacial muscle induces widespread mechanical allodynia

The role of trigeminal interpolaris-caudalis transition zone in persistent orofacial pain

Immune regulation of central nervous system functions: from sickness responses to pathological pain

Glial-cytokine-neuronal interactions underlying the mechanisms of persistent pain

Muscle IL1β drives ischemic myalgia via ASIC3-mediated sensory neuron sensitization

P2X4 receptors on muscle macrophages are required for development of hyperalgesia in an animal model of activity-induced muscle pain

Propentofylline, a CNS glial modulator does not decrease pain in post-herpetic neuralgia patients: in vitro evidence for differential responses in human and rodent microglia and macrophages

Evidence for brain glial activation in chronic pain patients

Renegade homeostatic cytokine responses in T1D: drivers of regulatory/effector T cell imbalance

TNFR2 promotes Treg-mediated recovery from neuropathic pain across sexes

Depletion of Foxp3+ regulatory T cells increases severity of mechanical allodynia and significantly alters systemic cytokine levels following peripheral nerve injury

Essential protective role of tumor necrosis factor receptor 2 in neurodegeneration

NF-KappaB pathway is involved in bone marrow stromal cell-produced pain relief

Studying sex and gender differences in pain and analgesia: a consensus report

Sex, gender, and pain: a review of recent clinical and experimental findings

Sex differences in pain and pain inhibition: multiple explanations of a controversial phenomenon

NIH. Consideration of Sex as a Biological Variable in NIH-Funded Research. Notice Number

Explaining sex differences in chronic musculoskeletal pain in a general population

Genes known to escape X chromosome inactivation predict co-morbid chronic musculoskeletal pain and posttraumatic stress symptom development in women following trauma exposure

Painful temporomandibular disorder: decade of discovery from OPPERA studies

Low back pain, a comprehensive review: pathophysiology, diagnosis, and treatment

Management of chronic musculoskeletal pain

Effective treatment options for musculoskeletal pain in primary care: a systematic overview of current evidence

Neuromuscular electrical stimulation (NMES) for patellofemoral pain syndrome

Effectiveness of myofascial release in treatment of chronic musculoskeletal pain: a systematic review

Autologous bone marrow concentrate intradiscal injection for the treatment of degenerative disc disease with three-year follow-up

Injections of concentrated bone marrow aspirate as treatment for discogenic pain: a retrospective analysis

Multipotent stromal cells for arthritic joint pain therapy and beyond

Mesenchymal stem cell-based therapy of osteoarthritis: current knowledge and future perspectives

Intra-articular injection of cultureexpanded mesenchymal stem cells with or without addition of platelet-rich plasma is effective in decreasing pain and symptoms in knee osteoarthritis: a controlled, double-blind clinical trial

Intratendinous injection of mesenchymal stem cells for the treatment of rotator cuff disease: a 2-year follow-up study

Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study

Stem cell therapies for treatment of discogenic low back pain: a comprehensive review

Voluntary biting behavior as a functional measure of orofacial pain in mice

Exosomes in perspective: a potential surrogate for stem cell therapy

Further observations on the behavioral and neural effects of bone marrow stromal cells in rodent pain models

In vivo immune interactions of multipotent stromal cells underlie their long-lasting pain-relieving effect. Sci Rep

Intravenous mesenchymal stem cell therapy for traumatic brain injury

Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the antiinflammatory protein TSG-6

Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy

Intrathecal bone marrow stromal cells inhibit neuropathic pain via TGF-β secretion

The traceability of mesenchymal stromal cells after injection into degenerated discs in patients with low back pain

A new mesenchymal stem cell (MSC) paradigm: polarization into a proinflammatory MSC1 or an Immunosuppressive MSC2 phenotype

Antinociceptive effect of intrathecal injection of miR-9-5p modified mouse bone marrow mesenchymal stem cells on a mouse model of bone cancer pain